Skip to content
back

Pharma at the Syntegon Group will take retirement

| 1 min read

Waiblingen (Germany), February 15, 2023.

Uwe Harbauer, Member of the Executive Board, Pharma has decided to resign as a member of the executive board of the Syntegon Group on May 30, 2023 and take early retirement. In this context, he has handed over his overall responsibility for the Pharma division as well as for sales excellence and enablement in the Syntegon Group to Dr. Michael Grosse, CEO of Syntegon, as of February 1, 2023. 

 

Until his retirement, Uwe Harbauer will take over various special tasks as a member of the Syntegon executive board.

Dr. Michael Grosse, CEO of the Syntegon Group would already like to express his sincere thanks for the extremely successful 23 years of service and Uwe Harbauer’s great achievements, especially in the very successful development of the Pharma division and wishes him all the best for the future.

 

Syntegon_Michael Grosse

Dr. Michael Grosse, CEO of Syntegon, took over the overall responsibility for the Pharma division.

 

 

 

Interested in our pharma solutions?

Interested in our pharma solutions?

Get in touch with us!
 
Worldwide contacts

Discover more about Syntegon

Accelerating time-to-market through COCREATION

Accelerate time-to-market with Ypsomed’s Clear-to-Clinic™ program and Syntegon’s flexible RMA assembly platform.

A trusted final assembly equipment partner

Discover how Syntegon and Ypsomed enable flexible final assembly, faster validation, and a smooth path from clinical batches to market launch.

Sepion: new standards in tablet coating

Syntegon’s Sepion series sets new standards in tablet coating with flexible batch sizes, OEB5 containment, reproducible processes, and easy scale-up from lab to production.